Catalyst Pharmaceuticals, Inc.
CPRX
$20.17
-$0.45-2.18%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 558.50M | 534.65M | 491.73M | 460.48M | 434.48M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 558.50M | 534.65M | 491.73M | 460.48M | 434.48M |
| Cost of Revenue | 94.77M | 88.19M | 81.49M | 73.83M | 149.10M |
| Gross Profit | 463.73M | 446.46M | 410.24M | 386.65M | 285.37M |
| SG&A Expenses | 182.93M | 177.71M | 177.74M | 175.58M | 163.26M |
| Depreciation & Amortization | 37.38M | 37.38M | 37.38M | 37.09M | 36.23M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 315.08M | 303.28M | 296.61M | 286.51M | 348.60M |
| Operating Income | 243.42M | 231.37M | 195.12M | 173.97M | 85.88M |
| Income Before Tax | 271.97M | 258.46M | 216.26M | 188.79M | 93.56M |
| Income Tax Expenses | 63.30M | 61.11M | 52.37M | 45.99M | 25.41M |
| Earnings from Continuing Operations | 208.67 | 197.35 | 163.89 | 142.80 | 68.15 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 208.67M | 197.35M | 163.89M | 142.80M | 68.15M |
| EBIT | 243.42M | 231.37M | 195.12M | 173.97M | 85.88M |
| EBITDA | 281.25M | 269.17M | 232.90M | 211.43M | 122.45M |
| EPS Basic | 1.73 | 1.65 | 1.38 | 1.24 | 0.58 |
| Normalized Basic EPS | 1.37 | 1.30 | 1.11 | 1.01 | 0.50 |
| EPS Diluted | 1.65 | 1.57 | 1.31 | 1.18 | 0.54 |
| Normalized Diluted EPS | 1.30 | 1.24 | 1.05 | 0.96 | 0.46 |
| Average Basic Shares Outstanding | 482.46M | 478.48M | 473.81M | 460.63M | 448.27M |
| Average Diluted Shares Outstanding | 506.19M | 503.30M | 499.75M | 487.22M | 468.38M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |